For the quarter ending 2025-09-30, EDIT had $25,899K increase in cash & cash equivalents over the period. -$31,276K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -25,117 | -129,323 |
| Stock-based compensation expense | 2,228 | 5,643 |
| Depreciation | 721 | 3,751 |
| Loss on disposal of fixed assets | 0 | -2,193 |
| Net accretion of discounts on marketable securities | 62 | 840 |
| Interest related to sale of future revenues | 2,399 | 4,236 |
| Impairment of held for sale assets | 0 | 3,724 |
| Other non-cash items | 0 | 390 |
| Accounts receivable | 7,542 | -15,678 |
| Prepaid expenses and other current assets | -593 | 418 |
| Right-of-use assets | -1,428 | -8,694 |
| Other non-current assets | -1 | -1,025 |
| Accounts payable | -3,561 | 1,231 |
| Accrued expenses | -543 | 2,271 |
| Accrued interest on sale of future revenues | 0 | -2,128 |
| Deferred revenue | 0 | -6,221 |
| Operating lease liabilities | -1,483 | -9,048 |
| Other non-current liabilities | 95 | 1,911 |
| Net cash used in operating activities | -30,843 | -98,011 |
| Purchases of property and equipment | 433 | 114 |
| Proceeds from the sale of equipment | 0 | 151 |
| Purchases of marketable securities | 0 | 0 |
| Proceeds from maturities of marketable securities | 40,006 | 99,000 |
| Net cash provided by investing activities | 39,573 | 99,037 |
| Repayment on sale of future revenues | 0 | 2,872 |
| Proceeds from issuance of common stock from at-the-market equity offering, net | 17,148 | 8,619 |
| Proceeds from exercise of stock options | 21 | 0 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 228 |
| Net cash provided by financing activities | 17,169 | 5,975 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 25,899 | 7,001 |
| Cash and cash equivalents at beginning of period | 135,418 | - |
| Cash and cash equivalents at end of period | 168,318 | - |
Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc. (EDIT)